Q-omics provides the consensus-scored DENND1C profile across patient tissues and cancer cell-line models. DENND1C expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, DENND1C is differentially expressed in 16, with the highest sampling consensus in STAD. Additionally, DENND1C protein abundance shows 20,077 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, STAD, and LSCC as cancer lineages where DENND1C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DENND1C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DENND1C survival associations across molecular data types. DENND1C RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DENND1C RNA expression–survival associations across cancer types. High DENND1C expression shows unfavorable associations in ACC, but favorable associations in HNSC, SKCM, KIRC, BLCA and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for DENND1C RNA expression.
This table summarizes DENND1C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for DENND1C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DENND1C shows lower tumor expression in COAD, LUSC, THCA and LUAD and higher tumor expression in STAD and BRCA. The STAD box plot shows higher DENND1C RNA expression in tumor versus normal tissue (log2 FC = +1.195, t-test p < 0.001).
This table shows molecular features associated with DENND1C in patient tissues and cancer cell lines. In patient samples, DENND1C shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, DENND1C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD.
